Sarah Cuddy

3.1k total citations · 1 hit paper
57 papers, 962 citations indexed

About

Sarah Cuddy is a scholar working on Molecular Biology, Nephrology and Physiology. According to data from OpenAlex, Sarah Cuddy has authored 57 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 22 papers in Nephrology and 18 papers in Physiology. Recurrent topics in Sarah Cuddy's work include Amyloidosis: Diagnosis, Treatment, Outcomes (43 papers), Parathyroid Disorders and Treatments (22 papers) and Sarcoidosis and Beryllium Toxicity Research (16 papers). Sarah Cuddy is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (43 papers), Parathyroid Disorders and Treatments (22 papers) and Sarcoidosis and Beryllium Toxicity Research (16 papers). Sarah Cuddy collaborates with scholars based in United States, Italy and United Kingdom. Sarah Cuddy's co-authors include Rodney H. Falk, Sharmila Dorbala, Raymond Y. Kwong, Michael Jerosch‐Herold, Ron Blankstein, Christoph Gräni, Vikram Agarwal, Ayaz Aghayev, Kyoichi Kaneko and Loïc Bière and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sarah Cuddy

41 papers receiving 943 citations

Hit Papers

Prognostic Value of Cardiac Magnetic Resonance Tissue Cha... 2017 2026 2020 2023 2017 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Cuddy United States 14 581 378 302 211 165 57 962
Fabian aus dem Siepen Germany 20 755 1.3× 545 1.4× 366 1.2× 121 0.6× 336 2.0× 53 1.3k
Jason Dungu United Kingdom 11 883 1.5× 294 0.8× 426 1.4× 141 0.7× 80 0.5× 34 1.1k
Aldostefano Porcari Italy 18 583 1.0× 482 1.3× 268 0.9× 107 0.5× 47 0.3× 90 1.0k
Keiko Ohta‐Ogo Japan 15 160 0.3× 413 1.1× 30 0.1× 58 0.3× 36 0.2× 61 661
Hirotaka Kimura Japan 10 171 0.3× 141 0.4× 32 0.1× 34 0.2× 51 0.3× 19 558
Megan Bright United States 11 103 0.2× 159 0.4× 44 0.1× 27 0.1× 136 0.8× 29 394
Yumiko Kanzaki Japan 15 147 0.3× 361 1.0× 12 0.0× 58 0.3× 97 0.6× 72 672
Moritz Mirna Austria 13 118 0.2× 209 0.6× 18 0.1× 53 0.3× 35 0.2× 57 508
Sei Tsunoda Japan 9 109 0.2× 173 0.5× 93 0.3× 23 0.1× 24 0.1× 29 580

Countries citing papers authored by Sarah Cuddy

Since Specialization
Citations

This map shows the geographic impact of Sarah Cuddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Cuddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Cuddy more than expected).

Fields of papers citing papers by Sarah Cuddy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Cuddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Cuddy. The network helps show where Sarah Cuddy may publish in the future.

Co-authorship network of co-authors of Sarah Cuddy

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Cuddy. A scholar is included among the top collaborators of Sarah Cuddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Cuddy. Sarah Cuddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Falk, Rodney H., Sarah Cuddy, & Osnat Itzhaki Ben Zadok. (2025). Silencers Versus Stabilizers in Amyloid Cardiomyopathy. Are We Asking the Wrong Questions?. European Journal of Heart Failure. 27(4). 623–627. 3 indexed citations
2.
Benz, Dominik C., Olivier Clerc, Sarah Cuddy, et al.. (2025). Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. JACC. Cardiovascular imaging. 18(12). 1363–1374.
3.
Kurian, Ashwin A., et al.. (2025). 124 I-Evuzamitide PET/CT Diagnosis of Wild-Type Transthyretin Amyloid Cardiomyopathy in a Woman With Negative Diagnostic Evaluation. Circulation Cardiovascular Imaging. 18(6). e017807–e017807.
4.
5.
Ioannou, Adam, Sarah Cuddy, Sharmila Dorbala, et al.. (2025). The Last Decade in Cardiac Amyloidosis. JACC. Cardiovascular imaging. 18(4). 478–499. 11 indexed citations
6.
Clerc, Olivier, Sarah Cuddy, Giada Bianchi, et al.. (2024). Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis. JACC. Cardiovascular imaging. 17(8). 911–922. 15 indexed citations
7.
Auer, Benjamin, Shilpa Vijayakumar, Olivier Clerc, et al.. (2024). Fully Automated Quantitation of 99mTc-PYP SPECT/CT Images Using Artificial Intelligence-Based Segmentation of Low-Dose CTAC. Journal of Nuclear Cardiology. 38. 101942–101942.
8.
Clerc, Olivier, et al.. (2024). Quantitative 99mTc-pyrophosphate myocardial uptake: Changes on transthyretin stabilization therapy. Journal of Nuclear Cardiology. 39. 102019–102019. 11 indexed citations
9.
Cuddy, Sarah, et al.. (2024). Current practices in amyloidosis imaging with bone-avid tracer cardiac scintigraphy. Journal of Nuclear Cardiology. 44. 102078–102078.
10.
Fumagalli, Carlo, Mathew S. Maurer, Marianna Fontana, et al.. (2024). Comprehensive Geriatric Assessment to Optimize the Management of Older Patients With Transthyretin Cardiac Amyloidosis. JACC Advances. 3(9). 101123–101123. 4 indexed citations
11.
Clerc, Olivier, Sarah Cuddy, Matthew Robertson, et al.. (2023). Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir. JACC. Cardiovascular imaging. 16(11). 1419–1432. 29 indexed citations
12.
Benz, Dominik C., Sarah Cuddy, Stephan Dobner, et al.. (2023). Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy. JACC. Cardiovascular imaging. 17(2). 195–211. 14 indexed citations
13.
Cuddy, Sarah, et al.. (2022). 99mTc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis. Radiology. 306(2). e221082–e221082. 16 indexed citations
14.
Cuddy, Sarah, Sean Murphy, Camden Bay, et al.. (2022). Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis. Circulation Cardiovascular Imaging. 15(11). e014645–e014645. 13 indexed citations
15.
Ge, Yin, Ankur Pandya, Sarah Cuddy, et al.. (2022). Modeling the Cost and Health Impacts of Diagnostic Strategies in Patients with Suspected Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association. 11(18). e026308–e026308. 6 indexed citations
16.
17.
Cuddy, Sarah, Michael Jerosch‐Herold, Rodney H. Falk, et al.. (2021). Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC. Cardiovascular imaging. 15(4). 594–603. 13 indexed citations
18.
Cuddy, Sarah, Paco E. Bravo, Rodney H. Falk, et al.. (2020). Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis. JACC. Cardiovascular imaging. 13(6). 1325–1336. 53 indexed citations
19.
Dorbala, Sharmila, Sarah Cuddy, & Rodney H. Falk. (2019). How to Image Cardiac Amyloidosis. JACC. Cardiovascular imaging. 13(6). 1368–1383. 168 indexed citations
20.
Cuddy, Sarah, David J. Murphy, Ruth Dunne, et al.. (2018). INCIDENTAL CORONARY ARTERY CALCIFICATION ON COMPUTERIZED TOMOGRAPHY IN PATIENTS WITH EARLY STAGE NON-SMALL CELL LUNG CANCER AND OPPORTUNITIES FOR CARDIOVASCULAR RISK OPTIMIZATION. Journal of the American College of Cardiology. 71(11). A1865–A1865. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026